Last reviewed · How we verify
PAN-301-1
At a glance
| Generic name | PAN-301-1 |
|---|---|
| Also known as | SNS-301 |
| Sponsor | Sensei Biotherapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN (PHASE1, PHASE2)
- Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients (PHASE1)
- SNS-301 Monotherapy in High Risk MDS and CMML (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PAN-301-1 CI brief — competitive landscape report
- PAN-301-1 updates RSS · CI watch RSS
- Sensei Biotherapeutics, Inc. portfolio CI